0

Shopping cart

0 items - €0.00

THE BEST WAY TO GENERATE CAR CELLS: LENTI-ONE VECTOR

Engineering the immune system may hold the key to the discovery and development of novel treatments for cancer, infectious diseases, and autoimmunity. For several decades, multiple ways have been explored but were limited by the genetic engineering tools made available.

Since the 2000s, the improvement of gene transfer tools allowed to explore new ways, including the T cells engineering that is overseeing the Chimeric Antigen Receptor T-cells (CAR T-cells).

CARs are recombinant receptors for antigen, which, in a single molecule, redirect the specific function of T lymphocytes and other immune cells bypassing the HLA recognition. Since the first generation of a CAR, several designs improvement have been done. Currently, there are three generations of CARs, all of which can be vectorized by GEG Tech.

 

three generations of CAR

Three generations of CARs. Left, first-generation CARs, including activating receptors such as CD8/CD3-ζ fusion receptors and T-bodies ; middle, second-generation CARs providing dual signaling to direct combined activating and costimulatory signals; right, third-generation CARs comprising more complex structures with 3 or more signaling domains. mAb, monoclonal antibody. (Sadelain et al. Cancer Discovery 2013)

 

For now, lentiviral vectors proved to be one of the best ways for T-cell engineering and CAR T-cells generation. However, there are multiple challenges to the engineering of CARs into T-cells, and GEG Tech is the partner of choice to guide and help you through them:

  • It requires stable gene transfer to enable sustained CAR expression in clonally expanding and persisting T-cells
  • The vector carrying the CAR transgene must be efficient enough to lead to a satisfactory expression
  • Toxicity issues must be solved in order to maximize the results
  • Safety concerns should be addressed to ensure the futur steps of the project

The R&D team of GEG Tech is constantly innovating, finding new ways to enhance efficiency, reduce toxicity, and improve safety. Through these innovations, we aim at always perfecting the CAR vectorization in order to ease the generation of effective CAR cells.

Recently, clinical successes have illustrated the power of the combination between lentiviral vectors and CARs (Porteur et al.N Engl J Med 2011, Kochenderfer et al. Blood 2012), rising credibility of CARs and making them a new class of drugs with exciting potential for cancer immunotherapy. Furthermore many studies in the field investigates the design of CARs against several antigens as shown in the following table.

 

Target
Construction
Type of histology
Type of study
Reference

CD19
ScFv – 4-1BB – CD3 ζ (Penn)
ALL
Phase 1
ScFv – CD28 – CD3ζ (MSKCC)
ALL
Phase 1
ScFv – CD28 – CD3ζ (NCI)
ALL
Phase 1
ScFv – 4-1BB – CD3 ζ
CLL
Phase 1
CD33/CD123
ScFv – CD28OX40 - CD3ζ
AML
In vivo
CD138
ScFv - CD3ζ (NK)
Multiple myeloma
In vivo
CD30
ScFv – CD3ζ (EBV)
Hodgkin
In vivo
NY-ESO-1
ScFv – CD28 – CD3ζ
Multiple myeloma
In vivo
α-Folate receptor
ScFv - FcεRIγ
Ovarian cancer
Phase 1
CEA
ScFv – CD28 – CD3ζ
Colorectal cancer
Phase 1
Erb-B2,3,4
ScFv – CD28 – CD3ζ
Breast  cancer
In vitro
Her2
ScFv – CD3ζ
Medulloblastoma
In vivo
ScFv – CD28 – CD3ζ
Sarcoma
In vivo
MAGE-A1
ScFv – CD28 - FcεRIγ
Melanoma
In vitro
Mesotheline
ScFv – 4-1BB – CD3ζ
Mesothelin
In vivo
PSMA
ScFv – CD28 – CD3ζ
Prostate cancer
In vitro
PSCA
ScFv – β2 – CD3ζ
Prostate cancer
In vitro

 

GEG Tech can easily step in to help vectorize your favorite CAR.

See the On-Demand - Advanced Program   -   Contact us to discuss CAR T-Cell